Longitude Capital
Longitude Capital is a venture growth investment firm that provides capital and strategic support to biotechnology, medical technology, and health solutions companies. Since 2006 the firm has raised over $2 billion across six funds. It targets clinical- and commercial-stage companies with clinically de‑risked assets, sources opportunities through industry relationships and thematic research, and uses a range of equity and equity-linked investment structures. Post-investment, the firm collaborates with management teams to set strategy, reach operating milestones, build teams, raise capital, and pursue liquidity.
Industries
Nr. of Employees
small (1-50)
Longitude Capital
2740 Sand Hill Road, 2nd Floor, Menlo Park, CA 94025
Portfolio
Biopharmaceutical company focused on NASH and other liver and metabolic disorders.
#Biotechnology
Clinical-stage biopharmaceutical company developing a proprietary botulinum toxin complex.
#Biotechnology
Clinical-stage company developing treatments for CLDN1+ tumors and organ fibrosis.
#Biotechnology
Developing imaging and therapeutic molecules for solid and hematologic cancers.
#Biotechnology
Commercializes and develops therapeutics to improve cardiovascular health.
#Biotechnology
Discovery and development of biologics, protein and peptide therapeutics.
#Biotechnology
Developed helical anchor technology for endovascular aneurysm repair (acquired by Medtronic in 2015).
#Medical Technology
Developed implantable devices for glaucoma (acquired by Allergan in 2015).
#Medical Technology
Developing the LOCOcyte cell-therapy platform for continuous local dosing of immunotherapeutics.
#Biotechnology
Developing immunomodulators using a HALOS nanotechnology platform to address chronic inflammation.
#Biotechnology
Developed a miniaturized rechargeable implantable neuromodulation technology for urinary and fecal dysfunction.
#Medical Technology
Clinical-stage company developing therapies for obesity and metabolic diseases using aging biology.
#Biotechnology
Developed and marketed Ofirmev (intravenous acetaminophen); acquired by Mallinckrodt in 2014.
#Biotechnology / Specialty Pharmaceuticals
Marketed genomic tests to assist cardiologists in assessing and treating cardiovascular disease.
#Biotechnology / Diagnostics
Developed CVT-301 for Parkinson’s disease (acquired by Acorda in 2014).
#Biotechnology
Provides digital solutions to transform utilization management and collaborative care journeys.
#Health Solutions / Digital Health
Develops abuse-deterrent pharmaceutical products for chronic pain.
#Biotechnology / Specialty Pharmaceuticals
Provides holistic solutions for children with autism and other neurodevelopmental conditions.
#Health Solutions / Technology-enabled care
Provides liquidity and financing solutions to royalty owners and companies in healthcare.
#Health Finance / Royalty Financing
Focused on discovery and development of therapies to treat neurodegenerative diseases.
#Biotechnology
Orphan drug accelerator identifying and de-risking programs.
#Biotechnology / Orphan drug accelerator
Clinical-stage company developing conditionally activated, masked biologics localized to the tumor microenvironment (NASDAQ: CTMX).
#Biotechnology
Developed machine-learning algorithms as predictive biomarkers for complex medical conditions.
#Health / Machine learning diagnostics
Clinical-stage company developing therapeutics that promote mitochondrial biogenesis and function.
#Biotechnology
Developing oral LDL-C lowering therapies to treat hypercholesterolemia without statins.
#Biotechnology
Developing the Norm™ heart failure management system for physician-directed self-management.
#Medical Technology
Provides cellular services for fertility and cellular therapy sectors (formerly California Cryobank Life Sciences).
#Health / Cell services
Tech-enabled solution addressing nursing workforce and provider staffing needs.
#Health Solutions / Workforce platform
Develops and markets specialty pharmaceuticals for neurological and oncologic conditions.
#Biotechnology
Commercializing a modernized Wearable Cardioverter Defibrillator.
#Medical Technology
Developing monoclonal antibodies targeting IL-11 receptor for fibrosis and inflammation.
#Biotechnology
Minimally-invasive technology for chronic limb-threatening ischemia; exited (acquired by Inari Medical).
#Medical Technology
Commercializing the Vivistim System, a vagus nerve stimulation therapy to improve post-stroke motor function.
#Medical Technology
Cloud-based SaaS platform for clinicians managing patients with implantable cardiac devices.
#Health Solutions / SaaS
Digital platform to identify and manage obsessive-compulsive disorder.
#Health Solutions / Digital therapeutics
Developed the System One device for home-based hemodialysis (exited).
#Medical Technology
Partners with primary care practices to provide clinical and administrative support for value-based care transitions.
#Health Solutions
Discovering small molecule inhibitors targeting FMRP for cancer immunotherapy.
#Biotechnology
Developed the first electronically focusing progressive lens (exited).
#Medical Technology
Translating gene engineering technologies into CAR T-cell and gene therapies (exited).
#Biotechnology
Markets diagnostic assays to tailor oncology chemotherapy regimens.
#Diagnostics / Biotechnology
Creates products to detect microbial contamination in pharmaceutical and biotech manufacturing.
#Life sciences tools / Medical Technology
Developed disposable devices to prevent accidental bowel leakage (exited).
#Medical Technology
Clinical-stage company focused on cardiometabolic diseases driven by obesity.
#Biotechnology
Developed energy-based aesthetic devices (acquired by Valeant in 2014).
#Medical Technology
Provides concierge kidney care to delay or prevent progression of chronic kidney disease.
#Health Solutions / Services
Developing pan-variant tyrosine kinase inhibitors for treatment-resistant cancer (exited).
#Biotechnology
Developing cellular therapies for organ transplantation and severe autoimmune disorders.
#Biotechnology
Developed devices for transcatheter mitral valve replacement (acquired by Medtronic in 2015).
#Medical Technology
Developing conjugate and protein-based vaccines for infectious diseases (exited).
#Biotechnology
Developed products for overactive bladder and irritable bowel syndrome (exited).
#Biotechnology
Developed devices to induce mild therapeutic hypothermia in heart attack and cardiac arrest patients.
#Medical Technology
Markets products for reduction of facial wrinkles, rhytides and cellulite.
#Medical Technology / Aesthetics
Clinical-stage company focused on treatments for immunological and inflammatory diseases.
#Biotechnology
Clinical-stage company developing therapeutics for dermatologic conditions.
#Biotechnology / Dermatology
Provides comprehensive care for medically frail seniors to improve outcomes at lower cost.
#Health Solutions / Services
Developing therapies for endocrinology, neurology, and gastroenterology (NASDAQ: XERS).
#Biotechnology
View All Portfolio ItemsShow less
Biopharmaceutical company focused on NASH and other liver and metabolic disorders.
#Biotechnology
Clinical-stage biopharmaceutical company developing a proprietary botulinum toxin complex.
#Biotechnology
Clinical-stage company developing treatments for CLDN1+ tumors and organ fibrosis.
#Biotechnology
Developing imaging and therapeutic molecules for solid and hematologic cancers.
#Biotechnology
Commercializes and develops therapeutics to improve cardiovascular health.
#Biotechnology
Discovery and development of biologics, protein and peptide therapeutics.
#Biotechnology
Developed helical anchor technology for endovascular aneurysm repair (acquired by Medtronic in 2015).
#Medical Technology
Developed implantable devices for glaucoma (acquired by Allergan in 2015).
#Medical Technology
Developing the LOCOcyte cell-therapy platform for continuous local dosing of immunotherapeutics.
#Biotechnology
Developing immunomodulators using a HALOS nanotechnology platform to address chronic inflammation.
#Biotechnology
Developed a miniaturized rechargeable implantable neuromodulation technology for urinary and fecal dysfunction.
#Medical Technology
Clinical-stage company developing therapies for obesity and metabolic diseases using aging biology.
#Biotechnology
Developed and marketed Ofirmev (intravenous acetaminophen); acquired by Mallinckrodt in 2014.
#Biotechnology / Specialty Pharmaceuticals
Marketed genomic tests to assist cardiologists in assessing and treating cardiovascular disease.
#Biotechnology / Diagnostics
Developed CVT-301 for Parkinson’s disease (acquired by Acorda in 2014).
#Biotechnology
Provides digital solutions to transform utilization management and collaborative care journeys.
#Health Solutions / Digital Health
Develops abuse-deterrent pharmaceutical products for chronic pain.
#Biotechnology / Specialty Pharmaceuticals
Provides holistic solutions for children with autism and other neurodevelopmental conditions.
#Health Solutions / Technology-enabled care
Provides liquidity and financing solutions to royalty owners and companies in healthcare.
#Health Finance / Royalty Financing
Focused on discovery and development of therapies to treat neurodegenerative diseases.
#Biotechnology
Orphan drug accelerator identifying and de-risking programs.
#Biotechnology / Orphan drug accelerator
Clinical-stage company developing conditionally activated, masked biologics localized to the tumor microenvironment (NASDAQ: CTMX).
#Biotechnology
Developed machine-learning algorithms as predictive biomarkers for complex medical conditions.
#Health / Machine learning diagnostics
Clinical-stage company developing therapeutics that promote mitochondrial biogenesis and function.
#Biotechnology
Developing oral LDL-C lowering therapies to treat hypercholesterolemia without statins.
#Biotechnology
Developing the Norm™ heart failure management system for physician-directed self-management.
#Medical Technology
Provides cellular services for fertility and cellular therapy sectors (formerly California Cryobank Life Sciences).
#Health / Cell services
Tech-enabled solution addressing nursing workforce and provider staffing needs.
#Health Solutions / Workforce platform
Develops and markets specialty pharmaceuticals for neurological and oncologic conditions.
#Biotechnology
Commercializing a modernized Wearable Cardioverter Defibrillator.
#Medical Technology
Developing monoclonal antibodies targeting IL-11 receptor for fibrosis and inflammation.
#Biotechnology
Minimally-invasive technology for chronic limb-threatening ischemia; exited (acquired by Inari Medical).
#Medical Technology
Commercializing the Vivistim System, a vagus nerve stimulation therapy to improve post-stroke motor function.
#Medical Technology
Cloud-based SaaS platform for clinicians managing patients with implantable cardiac devices.
#Health Solutions / SaaS
Digital platform to identify and manage obsessive-compulsive disorder.
#Health Solutions / Digital therapeutics
Developed the System One device for home-based hemodialysis (exited).
#Medical Technology
Partners with primary care practices to provide clinical and administrative support for value-based care transitions.
#Health Solutions
Discovering small molecule inhibitors targeting FMRP for cancer immunotherapy.
#Biotechnology
Developed the first electronically focusing progressive lens (exited).
#Medical Technology
Translating gene engineering technologies into CAR T-cell and gene therapies (exited).
#Biotechnology
Markets diagnostic assays to tailor oncology chemotherapy regimens.
#Diagnostics / Biotechnology
Creates products to detect microbial contamination in pharmaceutical and biotech manufacturing.
#Life sciences tools / Medical Technology
Developed disposable devices to prevent accidental bowel leakage (exited).
#Medical Technology
Clinical-stage company focused on cardiometabolic diseases driven by obesity.
#Biotechnology
Developed energy-based aesthetic devices (acquired by Valeant in 2014).
#Medical Technology
Provides concierge kidney care to delay or prevent progression of chronic kidney disease.
#Health Solutions / Services
Developing pan-variant tyrosine kinase inhibitors for treatment-resistant cancer (exited).
#Biotechnology
Developing cellular therapies for organ transplantation and severe autoimmune disorders.
#Biotechnology
Developed devices for transcatheter mitral valve replacement (acquired by Medtronic in 2015).
#Medical Technology
Developing conjugate and protein-based vaccines for infectious diseases (exited).
#Biotechnology
Developed products for overactive bladder and irritable bowel syndrome (exited).
#Biotechnology
Developed devices to induce mild therapeutic hypothermia in heart attack and cardiac arrest patients.
#Medical Technology
Markets products for reduction of facial wrinkles, rhytides and cellulite.
#Medical Technology / Aesthetics
Clinical-stage company focused on treatments for immunological and inflammatory diseases.
#Biotechnology
Clinical-stage company developing therapeutics for dermatologic conditions.
#Biotechnology / Dermatology
Provides comprehensive care for medically frail seniors to improve outcomes at lower cost.
#Health Solutions / Services
Developing therapies for endocrinology, neurology, and gastroenterology (NASDAQ: XERS).
#Biotechnology